Dual biological treatments in immune-mediated disorders: a single center experience
Abstract Background Physicians may encounter situations where they need to co-administer omalizumab with non–IgE-targeting monoclonal antibodies. In this study, we share our experience with these dual biologic treatments. Objective To evaluate the efficacy and safety of dual biological therapy using...
Збережено в:
| Автори: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
BMC
2025-04-01
|
| Серія: | BMC Immunology |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1186/s12865-025-00705-8 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|